3 unchanged sentences
Based upon information supplied from our transfer agent, there were approximately 869 shareholders of record of our Common Stock as of February 21, 2022.
−Removed: We have not paid any cash dividends and do not anticipate paying any cash dividends on our Common Stock in the foreseeable future.
Stock Performance Graph
1 unchanged sentence
ASSUMES $100 INVESTED ON DEC.
−Removed: ASSUMES NO DIVIDENDS
+Added: ASSUMES DIVIDEND REINVESTMENT;
+Added: NO DIVIDENDS ISSUED BY MIMEDX
FISCAL YEAR ENDED DEC.
+Added: Securities Authorized for Issuance Under Equity Compensation Plans
+Added: Information about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.
+Added: Recent Sales of Unregistered Securities
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
8 unchanged sentences
Total for the quarter — $ — — $ —
−Removed: 108,407 $ 6.46 — $ —
−Removed: (1) Shares repurchased during the quarter include shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock as well as restricted stock yielded to the Company to exercise stock options.
−Removed: Selected Financial Data
−Removed: The selected consolidated financial data displayed below for the years ended December 31, 2020, 2019, and 2018 was derived from our audited consolidated financial statements for the three-year period ended December 31, 2020.
−Removed: As described below, the selected financial data as of and for the year ended December 31, 2017 and 2016 have been derived from our restated audited consolidated financial statements, which reflect the impact of adjustments to, or restatement of, our previously-filed financial information.
−Removed: The selected financial data set forth below is not necessarily indicative of results of future operations, and should be read in conjunction with Item 7, “ Management’s Discussion and Analysis of Financial Condition and Results of Operations ” and the Consolidated Financial Statements .
−Removed: Year Ended December 31, in thousands
−Removed: 2020 (1) (3) (5)
−Removed: Statement of Operations Data:
−Removed: $ 248,234 $ 299,255 $ 359,111 $ 321,139 $ 221,712
−Removed: Gross profit 208,904 256,174 322,725 285,920 190,774
−Removed: Operating (loss) income
−Removed: (45,398) (21,160) (3,924) 46,223 884
−Removed: Net (loss) income
−Removed: $ (49,284) $ (25,580) $ (29,979) $ 64,727 $ 390
−Removed: Net (loss) income per common share - basic
−Removed: $ (0.77) $ (0.24) $ (0.28) $ 0.61 $ 0.00
−Removed: Net (loss) income per common share - diluted
−Removed: $ (0.77) $ (0.24) $ (0.28) $ 0.56 $ 0.00
−Removed: (1) Includes the adjustments discussed in Item 8, Note 2 “ Significant Accounting Policies—Revenue Recognition ”
−Removed: (2) Includes sales to external customers by Stability Biologics, LLC, our wholly-owned subsidiary acquired on January 13, 2016 and sold on September 30, 2017, were $7.0 million and $11.7 million during the years ended December 31, 2017 and 2016, respectively.
−Removed: (3) Includes legal fees, forensic audit fees, and consulting fees relating to the Restatement;
−Removed: and legal fees relating to the SEC Investigation, shareholder derivative lawsuits, as well as expenses paid under indemnification agreements with certain former members of management.
−Removed: (4) Includes Loss on sale of Stability Biologics, LLC of $1.0 million recognized during the year ended December 31, 2017.
−Removed: (5) Includes Loss on extinguishment of BT Term Loan of $8.2 million.
−Removed: For information regarding the comparability of the financial data presented in the tables above and factors that may impact comparability of future results, see Item 7.
−Removed: “ Management’s Discussion and Analysis of Financial Condition and Results of Operations ” as well as the Consolidated Financial Statements.
−Removed: As of December 31, in thousands
−Removed: 2020 2019 2018 2017 2016
−Removed: Balance Sheet Data:
−Removed: Cash and cash equivalents $ 95,812 $ 69,069 $ 45,118 $ 27,476 $ 30,321
−Removed: Accounts receivable, net 35,423 32,327 — — 1,927
−Removed: Inventory, net 10,361 9,104 15,986 9,467 15,872
−Removed: Prepaid expenses 5,605 6,669 6,673 2,125 1,838
−Removed: Income tax receivable 10,045 18 454 656 $ —
−Removed: Other current assets 3,371 6,058 5,818 9,023 9,516
−Removed: Total current assets 160,617 123,245 74,049 48,747 59,474
−Removed: Total assets $ 202,032 $ 167,166 $ 122,844 $ 121,255 $ 117,274
−Removed: Current portion of long term debt $ — $ 3,750 $ — $ — $ —
−Removed: Accounts payable 8,765 8,710 14,864 8,454 12,412
−Removed: Accrued compensation 18,467 21,302 23,024 20,941 12,691
−Removed: Accrued expenses 30,460 32,161 31,842 15,768 19,207
−Removed: Current portion of earn out liability — — — — 8,260
−Removed: Deferred tax liability — — — — 1,129
−Removed: Income taxes — — — — 5,611
−Removed: Other current liabilities 1,470 1,399 1,817 647 1,482
−Removed: Total current liabilities 59,162 67,322 71,547 45,810 60,792
−Removed: Long term liabilities $ 51,452 $ 65,446 $ 1,642 $ 1,648 $ 8,415
−Removed: Convertible preferred stock 91,568 — — — —
−Removed: Additional paid in capital 158,610 147,231 164,744 164,649 161,481
−Removed: Accumulated deficit (151,424) (102,140) (76,560) (46,581) (111,308)
−Removed: Total stockholders’ (deficit) equity (150) 34,398 49,655 73,797 48,067
−Removed: Total liabilities, convertible preferred stock, and stockholders’ (deficit) equity $ 202,032 $ 167,166 $ 122,844 $ 121,255 $ 117,274
−Removed: Working capital $ 101,455 $ 55,923 $ 2,502 $ 2,937 $ (1,318)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.